Ciphergen Biosystems Announces Results of Annual Meeting
July 06 2007 - 10:00AM
PR Newswire (US)
FREMONT, Calif., July 6 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announced today that at its annual
meeting held on June 29, 2007, its stockholders elected Michael J.
Callaghan, Kenneth J. Conway, and James L. Rathmann as Class I
directors for three-year terms and ratified the appointment of
PricewaterhouseCoopers LLP as the Company's independent registered
public accounting firm for the year ending December 31, 2007.
Ciphergen stockholders also approved amendments to the company's
certificate of incorporation to increase the authorized shares of
capital stock to 155,000,000 and the authorized number of shares of
common stock to 150,000,000, and to change the name of the company
to Vermillion, Inc. In connection with the name change, which is
expected to become effective mid-August 2007, the company has
reserved the Nasdaq ticker symbol VRML. "We believe the name change
reflects the significant transformation that has occurred over the
last year, and provides a new foundation from which to build a
high-value diagnostics company," said Gail S. Page, Chief Executive
Officer and President. "Vermillion signifies health, life, passion
and our commitment to improving patient health." About Ciphergen
Ciphergen Biosystems, Inc. is dedicated to the discovery,
development and commercialization of novel high-value diagnostic
tests that help physicians diagnose, treat and improve outcomes for
patients. Ciphergen, along with its scientific collaborators, has
ongoing diagnostic programs in oncology/hematology, cardiology and
women's health with an initial focus in ovarian cancer. Ciphergen
is based in Fremont, California. More information about Ciphergen
can be found on the Web at: http://www.ciphergen.com/. Safe Harbor
Statement This news release contains forward-looking statements
that involve significant risks and uncertainties, including those
that can be found in Ciphergen's Form 10-K for the year ended
December 31, 2006, and in Ciphergen's periodic reports on Form 10-Q
and Form 8-K. Statements in this release are based upon information
available to Ciphergen as of the date of the release. Information
and announcements involving Ciphergen's expectations, beliefs,
hopes, plans, intentions or strategies regarding the future are
forward- looking statements for purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995. We claim the protection of such safe harbor, and disclaim any
intent or obligation to update any forward- looking statement
contained in this document as a result of new information, future
events or otherwise. These statements are not guarantees of future
performance and actual results could differ materially from our
current expectations. NOTE: Ciphergen is a registered trademark of
Ciphergen Biosystems, Inc. DATASOURCE: Ciphergen Biosystems, Inc.
CONTACT: Lori Murray of WeissComm Partners, +1-415-946-1070, for
Ciphergen Biosystems, Inc.; or investors, Sue Carruthers of
Ciphergen Biosystems, Inc., +1-510-505-2235 Web site:
http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jul 2023 to Jul 2024